Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

June 19, 2019
Paul B. Chapman, MD

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Related Content:

ASCO Annual Meeting: MelanomaMelanoma
Chronic IRAEs With Adjuvant Anti–PD-1 Therapy More Common Than Previously Understood for Resected Melanoma
Phase 1/2 trial of Darovasertib With or Without Binimetinib Is Feasible, Safe for Metastatic Uveal Melanoma
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma